African American individuals have a greater incidence of atherosclerotic cardiovascular disease (ASCVD) compared with white individuals
1 yet are less likely to receive guideline-recommended statin therapy.
2 Beliefs regarding statin safety and effectiveness,
2 along with reports raising concerns about statin overtreatment owing to risk overestimation in African American and white individuals with predicted 10-year ASCVD risk of 7.5% or higher,
3 may result in reluctance of patients to adhere to statin therapy. To this end, the 2018 American College of Cardiology/American Heart Association (ACC/AHA) guidelines
4 recommend consideration of a non-0 coronary artery calcium (CAC) score to guide statin therapy for primary ASCVD prevention in adults with an intermediate risk for ASCVD and no other risk factors that automatically lead to statin therapy indication (eg, diabetes) (Figure 1).